ClinicalTrials.gg
RecruitingNCT06703606Updated Oct 15, 2026

A Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A.

A Phase 1 interventional study of MARSTACIMAB in Severe Hemophilia A, sponsored by Pfizer. Recruiting at 10 sites in 3 countries. Open to male participants aged 12 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 15, 20263 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
12 Years to 74 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Hemophilia A by Pfizer — 6 open to participants now, 9 under way, 6 of them phase 3. Hemophilia A · Pfizer.

Planned enrollment
24th of 32
15 · median 34
Started
2025
with 2 others
Phase 1
5 of 47
1 open now
Registered
44th of 47
by date

Among the 47 studies in Hemophilia A by Pfizer, this one is the 24th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 1, and was the 44th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

6 of the 47 studies in Hemophilia A by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years to 74 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Hemophilia A by Pfizer, or all of them as a file.
02

Study summary

The purpose of the study is to learn about safety, how the body processes marstacimab and how it works in patients with severe hemophilia A without inhibitors. Hemophilia A is rare bleeding disorder where the blood doesn't clot normally. This causes a person to bleed a lot, even from a small cut.

These patients who are on emicizumab medicine for routine prophylaxis for at least 6 months, and desire to switch to marstacimab medicine. Inhibitors are antibodies that the immune system develops because it sees the infused clotting factor as a foreign substance that needs to be destroyed. Antibodies are proteins that eat up the activated factor before it has time to stop the bleeding. Prophylaxis are preventive medicines.

This study is seeking for participants:

  • with severe Hemophilia A withouth inhibitors who are on emicizumab treatment for at least 6 months.
  • must be 12 to less than 75 years old
  • must have a body weight of at least 35 kilograms. The results from this study will serve as a guide to doctors and their hemophilia A patients who will change their medicines in the real-world clinical setting. Patients who can take part in the study will receive marstacimab medicine as weekly injections under the skin of 150 milligrams for 4 months. Study treatment with marstacimab will be initiated no earlier than 14 days after last dose of emicizumab. The study can last up to 6 months. The sponsor will provide marstacimab. Patients will continue their usual treatment with the infused clotting factor for their bleeds when taking part in the study. Roll-over into an optional study treatment extension period will be available to participants who wish to continue prophylaxis with marstacimab in countries where it is not commercially available.
Read the detailed description

This is a non-randomized open-label study in approximately 10-15 adolescent and adult participants between ages 12 to \<75 years with severe hemophilia A (defined as FVIII activity \<1%) without inhibitors who are currently on treatment with emicizumab for ≥6 months. The study is designed to assess the safety and PK/PD during a 4-month treatment period with marstacimab 150 mg SC QW after a minimum 14-day wash-out period following discontinuation of emicizumab. Assessment of safety will be conducted by summarizing AEs and SAEs reported during the study, from the time each participant provides informed consent through and including a minimum of 28 calendar days after last dose of study intervention. Participants will continue to use their standard of care factor replacement for breakthrough bleeds during the course of the study. PK, PD, and ADA measurements will support the clinical safety data. The anticipated study duration for an individual participant is approximately 6 months. After completion of marstacimab treatment period participants will resume their standard of care prophylactic treatment after a 14-day wash-out period following the last dose of marstacimab. Roll-over into an optional study treatment extension period will be available to participants who wish to continue prophylaxis with marstacimab in countries where it is not commercially available.

03

Conditions studied

  • Severe Hemophilia A

Browse trials for

Keywords

  • Hemophilia A
  • Severe Hemophilia A
  • Severe Hemophilia A Without Inhibitors
04

Who can participate

Ages eligible
12 Years to 74 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and 12 to \<75 years of age with a minimum body weight of 35 kg at the time of signing the .
  2. Diagnosis of severe hemophilia A (FVIII activity \<1%) without inhibitors.
  3. On emicizumab therapy at a standard clinical dose for ≥6 months.

Exclusion criteria

Exclusion Criteria:

  1. Previous or current treatment for or history of coronary artery diseases, venous or arterial thrombosis, or ischemic disease.
  2. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  3. Known hemostatic defect other than hemophilia A.
  4. Current use of any prohibited concomitant medication(s) or unwillingness or inability to use a required concomitant medication(s).
  5. Previous administration of an product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.
  6. count \<100,000/μl or \<10 g/dL.
  7. renal or hepatic function abnormality based on laboratory results at screening, or known kidney or liver disease.
  8. ≤200/μl if positive.
  9. Screening 12-lead that demonstrates clinically significant abnormalities that, in the opinion of the investigator, may affect participant safety or interpretation of study results.
  10. Known planned surgical procedure.
  11. or allergic reaction to hamster protein or other components of the study intervention.
  12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor-delegate employees directly involved in the conduct of the study and their family members.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    MARSTACIMAB

    Marstacimab 150 mg subcutaneous (SC) once weekly (QW)

    Drug: MARSTACIMAB

Interventions

  • Marstacimab 150 mg administered subcutaneous (SC) once weekly (QW)

    Also known as: PF-06741086

06

What researchers measure

Primary outcomes

  1. Incidence of marstacimab-related adverse events (AEs)

    Time frame: Approximately 178 days: from the time the participant provides informed consent, through and including a minimum of 28 calendar days after last dose of study treatment

  2. Incidence of marstacimab-related serious AEs (SAEs)

    Time frame: Approximately 178 days: from the time the participant provides informed consent, through and including a minimum of 28 calendar days after last dose of study treatment

Secondary outcomes

  1. Plasma Concentration Versus Time of Marstacimab (Listings)

    Time frame: Day 1 up to day 135

  2. Maximum Observed Plasma Concentration (Cmax) of Marstacimab

    Time frame: Day 1 up to day 135

  3. Average Plasma Concentration (Cavg) of Marstacimab

    Time frame: Day 1 up to day 135

  4. Minimum Observed Plasma Concentration (Cmin)

    Time frame: Day 1 up to day 135

  5. Change from baseline in tissue factor pathway inhibitor (TFPI).

    Time frame: Baseline, Day 1 up to day 135

  6. Change from baseline in prothrombin fragment 1+2 (PF 1+2)

    Time frame: Baseline, Day 1 up to day 135

  7. Change from baseline in D-dimer

    Time frame: Baseline, Day 1 up to day 135

  8. Change from baseline in TGA (thrombin generation assay).

    Time frame: Baseline, Day 1 up to day 135

  9. Incidence of Anti-Drug Antibody (ADA)

    Time frame: Day 1 up to day 135

  10. Incidence of clinically significant persistent neutralizing antibodies (NAb)

    Time frame: Day 1 up to day 135

07

Study locations

7 of 10 sites recruiting
  • Altman Clinical and Translational Research Institute-IDS
    La Jolla, California 92037, United States
    Not yet recruiting
  • Altman Clinical and Translational Research Institute
    La Jolla, California 92037, United States
    Not yet recruiting
  • Orthopaedic Institute for Children/Orthopaedic Hemophilia Treatment Center
    Los Angeles, California 90007, United States
    Recruiting
  • UCSD Center for Bleeding and Clotting Disorders
    San Diego, California 92121, United States
    Not yet recruiting
  • Brody School of Medicine at East Carolina University
    Greenville, North Carolina 27834, United States
    Recruiting
  • ECU Health Medical Center
    Greenville, North Carolina 27834, United States
    Recruiting
  • Nirmal Hospital Pvt Ltd.
    Surat, Gujarat 395002, India
    Recruiting
  • K J Somaiya Hospital & Research Centre
    Mumbai, Maharashtra 400022, India
    Recruiting
  • Ege University Faculty of Medicine Dean's Office
    Bornova, İzmir 35100, Turkey (Türkiye)
    Recruiting
  • Istanbul Universitesi Tıp Fakultesi Onkoloji Enstitusu
    Fatih, İ̇stanbul 34093, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.

Of 37 industry-sponsored phase 1 interventional studies under Hemophilia A, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's planned 23 months is above that.

Counting every sponsor, half of 46 studies reached it within 13 months; a quarter within 7 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Nov 25, 2024
StartActual
May 13, 2025
Primary completionEst.
May 5, 2027
CompletionEst.
May 5, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added
Show 3 added (3 United States)
  • Altman Clinical and Translational Research Institute-IDS · La Jolla, United States
  • Altman Clinical and Translational Research Institute · La Jolla, United States
  • UCSD Center for Bleeding and Clotting Disorders · San Diego, United States
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    3 sites added
    Show 3 added (3 United States)
    • Altman Clinical and Translational Research Institute-IDS · La Jolla, United States
    • Altman Clinical and Translational Research Institute · La Jolla, United States
    • UCSD Center for Bleeding and Clotting Disorders · San Diego, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06703606
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
May 13, 2025
Primary completion
May 5, 2027 (estimated)
Completion
May 5, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Marstacimab

Start the discussion